论文部分内容阅读
目的探讨血清糖类抗原125(carbohydrateantigen125,CA125)和血清肿瘤相关物质(tumor associated material,TAM)联合检测在妇科肿瘤诊断中的应用价值。方法选择2011年1月—2012年6月收治的妇科恶性肿瘤患者125例为恶性肿瘤组,良性肿瘤患者78例为良性肿瘤组,正常体检妇女96名为对照组,清晨空腹取静脉血3 ml,分别采用电化学发光法和化学比色法测定各组血清CA125和血清TAM的含量,比较各组阳性率、恶性肿瘤组单独及联合检测的灵敏度和特异度。结果恶性肿瘤组血清CA125和血清TAM含量分别为(105.84±16.12)、(208.04±138.8)U/ml均高于良性肿瘤组的(90.76±9.85)、(25.61±22.61)U/ml和对照组的(81.54±9.23)、(9.81±4.61)U/ml,比较差异均有统计学意义(均P<0.05)。恶性肿瘤组血清CA125和血清TAM阳性率分别为87.20%、52.00%均高于良性肿瘤组的21.79%、26.92%和对照组的2.08%、4.17%,差异均有统计学意义(均P<0.05)。恶性肿瘤组单独检测血清CA125阳性率52.00%,血清TAM阳性率87.20%,联合检测阳性率91.20%,单独检测阳性率与联合检测阳性率比较差异均有统计学意义(均P<0.05)。血清CA125和血清TAM测定对恶性肿瘤的灵敏度分别是52.00%和87.20%,特异度分别是85.63%和89.08%。二者联合检测的灵敏度和特异度分别为91.20%和87.36%。结论血清CA125和血清TAM联合检测不仅可以提高妇科恶性肿瘤的阳性诊断率,而且对妇科肿瘤良恶性的辅助诊断及鉴别诊断具有一定临床应用价值。
Objective To investigate the value of combined detection of carbohydrate antigen 125 (CA125) and serum tumor associated material (TAM) in the diagnosis of gynecological tumors. Methods A total of 125 patients with gynecologic malignancy admitted to our hospital from January 2011 to June 2012 were selected as malignant tumor group, 78 benign tumor patients as benign tumor group and 96 normal control women as control group. In the morning, The levels of serum CA125 and serum TAM in each group were determined by electrochemiluminescence and chemiluminescence method. The positive rate and the sensitivity and specificity of single and combined detection of malignant tumor were compared. Results The levels of serum CA125 and serum TAM in the malignant tumor group were (105.84 ± 16.12) and (208.04 ± 138.8) U / ml, respectively, which were significantly higher than those in the benign tumor group (90.76 ± 9.85) and (25.61 ± 22.61) U / (81.54 ± 9.23) and (9.81 ± 4.61) U / ml respectively, all with statistical significance (all P <0.05). The positive rates of serum CA125 and serum TAM in malignant tumor group were 87.20% and 52.00% respectively, which were significantly higher than those in benign tumor group (21.79%, 26.92% vs 2.08% and 4.17%, respectively) (all P <0.05 ). In the malignant tumor group, the positive rate of serum CA125 was 52.00%, the positive rate of serum TAM was 87.20%, and the positive rate of combined detection was 91.20%. There was significant difference between the positive rate of single detection and the positive rate of combined detection (all P <0.05). The sensitivity of serum CA125 and serum TAM to malignant tumors were 52.00% and 87.20% respectively, and the specificity was 85.63% and 89.08% respectively. The sensitivity and specificity of the combined detection of the two were 91.20% and 87.36% respectively. Conclusion The combined detection of serum CA125 and serum TAM can not only improve the positive diagnosis rate of gynecologic malignancies, but also have some clinical value in the diagnosis and differential diagnosis of benign and malignant gynecologic tumors.